iKang Healthcare Group, Inc. (“iKang” or the “Company”)
(Nasdaq:KANG), major provider in China’s fast growing private
preventive healthcare services market, today announced its
unaudited financial results for the fiscal third quarter ended
December 31, 2017.
Fiscal Third Quarter Ended December 31,
2017 Financial Highlights
- Net revenues were US$206.4 million, an increase of 33.5%
year-over-year (an increase of 29.3% on RMB basis) (1)
- Gross profit was US$104.9 million, an increase of 43.5%
year-over-year (an increase of 38.9% on RMB basis) (1)
- Net income attributable to the Company was US$27.1
million, an increase of 93.0% year-over-year (an increase of 86.8%
on RMB basis) (1)
- Non-GAAP net income attributable to the
Company(2) was US$27.5 million, an increase of 89.2%
year-over-year (an increase of 83.1% on RMB basis) (1)
- Basic and diluted income per ADS attributable to common
shareholders were US$0.39 and US$0.39, respectively, as
compared to US$0.21 and US$0.20, respectively, in the
fiscal third quarter of 2016
- Non-GAAP basic and diluted income per ADS(3) attributable
to common shareholders were US$0.40 and US$0.40,
respectively, as compared to US$0.21 and US$0.21,
respectively, in the fiscal third quarter of 2016
Fiscal Nine Months Ended December 31, 2017 Financial
Highlights
- Net revenues were US$474.4 million, an increase of 26.3%
year-over-year (an increase of 26.2% on RMB basis) (1)
- Gross profit was US$224.0 million, an increase of 30.2%
year-over-year (an increase of 29.9% on RMB basis) (1)
- Net income attributable to the Company was US$50.1
million, an increase of 127.7% year-over-year (an increase of
124.1% on RMB basis) (1)
- Non-GAAP net income attributable to the
Company(2) was US$51.3 million, an increase of 118.5%
year-over-year (an increase of 115.2% on RMB basis) (1)
- Basic and diluted income per ADS attributable to common
shareholders were US$0.73 and US$0.72, respectively, as
compared to US$0.32 and US$0.32, respectively, in the first
fiscal nine months of 2016
- Non-GAAP basic and diluted income per ADS(3) attributable
to common shareholders were US$0.75 and US$0.74,
respectively, as compared to US$0.35 and US$0.34,
respectively, in the first fiscal nine months of 2016
(1) RMB basis refers to the year on year
comparison made on local currency – Chinese Renminbi basis. (2)
Non-GAAP net income attributable to the Company is defined as net
income attributable to the Company excluding share-based
compensation expenses. For more information on these non-GAAP
financial measures, please see the section captioned under
“Non-GAAP Financial Measures” and the tables captioned
“Reconciliation of GAAP and Non-GAAP Results” set forth at the end
of this release. (3) Non-GAAP basic and diluted earnings per ADS is
defined as non-GAAP net income divided by the weighted average
number of basic and diluted ADS.
“We delivered another very strong quarter with
robust performance across all of our business, financial and
operation metrics,” said Mr. Lee Ligang Zhang, Chairman and Chief
Executive Officer of iKang. “The continuous growth and outstanding
performance are strong testaments to our strategic initiative of
building an ecosystem of preventive healthcare service with
iKangCare+ and iKangPartners+ plans and our focus on delivering
innovative and premium service to our customers.
“In this quarter, iKang recorded an exceptional
revenue growth of 33.5% year-over-year, supported by a 21.2%
increase in customer visits and increasing demand for both our core
and value-added services with the increase in the average selling
price for both individual and corporate customers. As our scale
continues to expand, service penetration continues to deepen and
operations of medical centers continue to mature, our operating
leverage has further enhanced and margins significantly increased.
Our gross profit margin increased to 50.8% from 47.3%, operating
margin to 23.1% from 17.4% and net profit margin to 13.1% from
9.1%.
"We have made great strides in executing our
strategic priorities of iKangCare+ and iKangPartners+ plans to
enable the Company to capitalize on the significant opportunity
ahead of us. Our energy and focus are on expanding our
geographical coverage, deepening market penetration in fast-growing
tier-2 and tier-3 cities, improving the utilization of our medical
centers, improving operational efficiency and introducing
additional value-added services to drive business expansion. We are
very excited about our significant short term and long term
opportunities as we continue to enhance our service differentiation
and market leadership to drive sustainable profitable growth.”
FISCAL THIRD QUARTER ENDED DECEMBER 31, 2017
UNAUDITED FINANCIAL RESULTS
Net Revenues Net
revenues for the fiscal third quarter were US$206.4 million,
representing a 33.5% increase from US$154.6 million in
the same period of the last fiscal year. On RMB basis, the
revenue growth was 29.3%. As of December 31, 2017, the number
of self-owned medical centers totaled 108 compared to 104 as
of December 31, 2016. In this quarter, the Company served
approximately a total of 2.40 million customer visits under both
corporate and individual programs, representing an increase of
21.2% over the fiscal third quarter of 2016.
The table below sets forth a breakdown of net revenues:
(US$ million) |
3rd Fiscal Quarter Ended
December 31, 2017 |
3rd Fiscal Quarter Ended
December 31, 2016 |
YoY % Change
|
Medical Examinations |
168.0 |
129.3 |
29.9% |
Disease Screening |
20.7 |
12.7 |
62.5% |
Dental Services |
5.9 |
3.2 |
83.0% |
Other Services |
11.8 |
9.3 |
28.0% |
Total |
206.4 |
154.6 |
33.5% |
Medical Examinations: Net revenues for the
quarter were US$168.0 million, representing a 29.9% increase
from US$129.3 million in the same period of the last fiscal
year.
Disease Screening: Net revenues for the
quarter were US$20.7 million, representing a 62.5% increase
from US$12.7 million in the same period of the last
fiscal year. Disease screening services refer to the additional
services requested by individuals under the basic corporate medical
examination programs as a result of individual needs.
Dental Services: Net revenues for the
quarter were US$5.9 million, representing an 83.0% increase
from US$3.2 million in the same period of the last fiscal
year.
Other Services: Net revenues for the
quarter were US$11.8 million, representing a 28.0% increase
from US$9.3 million in the same period of the last fiscal
year.
Cost of RevenuesCost of
revenues for the quarter was US$101.4 million, representing a
24.6% increase from US$81.4 million in the same period of
the last fiscal year.
Gross Profit and Gross
MarginGross profit for the quarter was US$104.9
million, representing a 43.5% increase from US$73.1
million in the same period of the last fiscal year. Gross
margin for the quarter was 50.8%, as compared to 47.3% in the third
quarter of the last fiscal year.
Operating ExpensesTotal
operating expenses for the quarter were US$57.2 million,
representing a 23.7% increase from US$46.2 million in the
same period of the last fiscal year.
Selling and marketing expensesSelling and
marketing expenses for the quarter were US$32.6 million,
accounting for 15.8% of total net revenues as compared to 13.9% in
the same period of the last fiscal year.
General and administrative expensesGeneral and
administrative expenses for the quarter were US$23.8 million,
accounting for 11.5% of total net revenues as compared to 15.4% in
the same period of the last fiscal year.
Research and development expensesResearch and
development expenses for the quarter were US$0.8, accounting
for 0.4% of total net revenues as compared to 0.6% in the same
period of the last fiscal year.
Income from OperationsIncome
from operations for the quarter was US$47.7 million,
representing a 77.4% increase from US$26.9 million in the
same period of the last fiscal year. Excluding share-based
compensation expenses of US$389,000 for this quarter and
US$489,000 for the same quarter last year, non-GAAP income from
operations for the quarter was US$48.1 million as
compared to US$27.4 million, which reflected an increase of
75.7%.
Non-GAAP EBITDANon-GAAP EBITDA
for the quarter was US$58.7 million, representing a 59.6% increase
from US$36.8 million in the same period of the last fiscal
year. Non-GAAP EBITDA margin for the quarter was 28.4% as
compared to 23.8% for the same quarter last year.
Net
Income Net income
attributable to the Company for the quarter was US$27.1
million, representing an increase of 93.0% from US$14.0
million in the same period of the last fiscal year.
Non-GAAP net income for the quarter
was US$27.5 million, representing an increase of 89.2%
from US$14.5 million in the same period of the last
fiscal year. Non-GAAP net income margin for the quarter was 13.3%
as compared to 9.4% for the same quarter last year.
Basic and Diluted Earnings per
ADSBasic and diluted income per ADS attributable to common
shareholders were US$0.39 and US$0.39, respectively, as
compared to US$0.21 and US$0.20, respectively, in the same quarter
of 2016.
Non-GAAP basic and diluted income per ADS
attributable to common shareholders were US$0.40 and US$0.40,
respectively, as compared to US$0.21 and US$0.21, respectively, in
the same quarter of 2016.
FIRST FISCAL NINE MONTHS ENDED DECEMBER 31,
2017 UNAUDITED FINANCIAL RESULTS
Net Revenues Net revenues for the
first fiscal nine months were US$474.4 million, representing
26.3% increase from US$375.6 million in the same period
of the last fiscal year. On RMB basis, the revenue growth was
26.2%. From the beginning of the year, we have added eight
new medical centers. During this period, the Company served
approximately a total of 5.64 million customer visits under both
corporate and individual programs, representing an increase of
16.7% over the first fiscal nine months of 2016.
The table below sets forth a breakdown of net
revenues:
(US$ million) |
First Fiscal Nine Months Ended December 31,
2017 |
First Fiscal Nine Months Ended December 31,
2016 |
YoY % Change |
Medical Examinations |
385.0 |
314.5 |
22.4% |
Disease Screening |
45.1 |
29.0 |
55.4% |
Dental Services |
13.4 |
6.9 |
93.3% |
Other Services |
30.9 |
25.1 |
23.2% |
Total |
474.4 |
375.6 |
26.3% |
Medical Examinations: Net revenues for the
period were US$385.0 million, representing a 22.4% increase
from US$314.5 million in the same period of last fiscal
year.
Disease Screening: Net revenues for the
period were US$45.1 million, representing a 55.4% increase
from US$29.0 million in the same period of last fiscal
year. Disease screening services refer to the additional services
requested by individuals under the basic corporate medical
examination programs as a result of individual needs.
Dental Services: Net revenues for the
period were US$13.4 million, representing a 93.3% increase
from US$6.9 million in the same period of the last fiscal
year.
Other Services: Net revenues for the period
were US$30.9 million, representing a 23.2% increase
from US$25.1 million in the same period of the last
fiscal year.
Cost of RevenuesCost of
revenues for the period was US$250.4 million, representing a
23.0% increase from US$203.6 million in the same period
of the last fiscal year.
Gross Profit and Gross
MarginGross profit for the period was US$224.0
million, representing a 30.2% increase from US$172.0
million in the same period in the last fiscal year. Gross
margin for the period was 47.2%, as compared to 45.8% in the same
period of the last fiscal year.
Operating ExpensesTotal
operating expenses for the period were US$134.9 million,
representing an 8.8% increase from US$123.9 million in
the same period of the last fiscal year.
Selling and marketing expensesSelling and
marketing expenses for the period were US$71.5 million,
accounting for 15.1% of total net revenues as compared to 15.0% in
the same period of the last fiscal year.
General and administrative expensesGeneral and
administrative expenses for the period were US$61.1 million,
accounting for 12.9% of total net revenues as compared to 17.3% in
the same period of the last fiscal year.
Research and development expensesResearch and
development expenses for the period were US$2.3 million,
accounting for 0.5% of total net revenues as compared to 0.7% in
the same period of the last fiscal year.
Income from OperationsIncome
from operations for the period was US$89.1 million,
representing an 85.4% increase from US$48.1 million in
the same period of the last fiscal year. On RMB Basis, the increase
was 83.1%. Excluding share-based compensation expenses
of US$1,162,000 for this period
and US$1,462,000 for the same period of the last year,
non-GAAP income from operations for the period was US$90.2 million
as compared to US$49.5 million, which reflected an increase of
82.2%.
Non-GAAP EBITDANon-GAAP EBITDA
for the period was US$121.4 million, representing a 57.7% increase
from US$77.0 million for the same period of the last fiscal
year. Non-GAAP EBITDA margin for the period was 25.6% as
compared to 20.5% for the same period last year.
Net
Income Net income
attributable to the Company for the period was US$50.1
million, representing an increase of 127.7% from US$22.0
million in the same period of the last fiscal year.
Non-GAAP net income for the period
was US$51.3 million, representing an increase of 118.5%
from US$23.5 million in the same period of the last
fiscal year. Non-GAAP net income margin for the period was 10.8% as
compared to 6.3% for the same period last year.
Basic and Diluted Earnings per
ADSBasic and diluted income per ADS attributable to common
shareholders were US$0.73 and US$0.72, respectively, as
compared to US$0.32 and US$0.32, respectively, in the first fiscal
nine months of 2016.
Non-GAAP basic and diluted income per ADS
attributable to common shareholders were US$0.75 and US$0.74,
respectively, as compared to US$0.35 and US$0.34, respectively, in
the first fiscal nine months of 2016.
Cash and Cash EquivalentsAs of
December 31, 2017, the Company’s cash and cash equivalents,
restricted cash and term deposit totaled US$77.7 million, as
compared to US$45.5 million as of September 30, 2017.
GUIDANCE FOR FISCAL YEAR 2017 ENDING
MARCH 31, 2018
For the fiscal year 2017 ending March 31, 2018,
the Company reaffirms its guidance of net revenue to be between
RMB3.57 billion and RMB3.72 billion, representing a year-on-year
increase between 22% and 27%.
This guidance is based on the current market
conditions and reflects the Company's current and preliminary
estimates of market and operating conditions and customer demand,
which are all subject to change.
Conference CalliKang’s
management will host a conference call at 8:00 am US Eastern Time
(8:00 pm Beijing/Hong Kong Time) on March 23, 2018, to discuss its
quarterly results and recent business activities.
To participate in the conference call, please
dial the following number five to ten minutes prior to the
scheduled conference call time:
China: |
4006-208-038 |
Hong
Kong: |
800-906-601 |
United States: |
186-6519-4004 |
International: |
+65
6713-5090 |
Passcode: |
7294807 |
|
|
The Company will also broadcast a live audio webcast of the
conference call. The webcast will be available at
http://ir.ikang.com/.
Following the earnings conference call, an
archive of the call will be available by dialing:
China: |
4006-322-162 |
Hong
Kong: |
800-963-117 |
United States: |
185-5452-5696 |
International: |
+61 2
8199-0299 |
Replay Passcode: |
7294807 |
Replay Available Date: |
11:00
ET March 23, 2018 – 08:59 ET March 31, 2018 |
|
|
About iKang Healthcare Group,
Inc. iKang Healthcare Group, Inc. is one of the
largest providers in China’s fast-growing private preventive
healthcare space through its nationwide healthcare services
network.
iKang’s nationwide integrated network of
multi-brand self-owned medical centers and third-party facilities,
provides comprehensive and high-quality preventive healthcare
solutions across China, including medical examination, disease
screening, outpatient service and other value-added services.
iKang’s customer base primarily comprises corporate clients, who
contract with iKang to deliver medical examination services to
their employees and clients, and receive these services at
pre-agreed rates. iKang also directly markets its services to
individual customers. In the fiscal year ended December 31, 2017,
iKang served a total of 5.64 million customer visits under both
corporate and individual programs.
As of March 22, 2018, iKang has a nationwide
network of 110 self-owned medical centers, covering 33 of China’s
most affluent cities: Beijing, Shanghai, Guangzhou, Shenzhen,
Chongqing, Tianjin, Nanjing, Suzhou, Hangzhou, Chengdu, Fuzhou,
Jiangyin, Changzhou, Wuhan, Changsha, Yantai, Yinchuan, Weihai,
Weifang, Shenyang, Xi’an, Wuhu, Guiyang, Ningbo, Foshan, Jinan,
Bijie, Qingdao, Wuxi, Kaili, Mianyang and Zhenjiang, as well as
Hong Kong. iKang has also extended its coverage to over 200 cities
by contracting with over 400 third-party facilities, which include
select independent medical examination centers and hospitals across
all of China’s provinces, creating a nationwide network that allows
iKang to serve its customers in markets where it does not operate
its own medical centers.
Forward-looking StatementsThis
press release contains forward-looking statements. These
statements, including management quotes and business outlook, are
made under the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements can be identified by terminology such as “will,”
"estimate," "project," "predict," "believe," "expect,"
"anticipate," "intend," "potential," "plan," "goal" and similar
statements. iKang may also make written or oral forward-looking
statements in its periodic reports to the U.S. Securities and
Exchange Commission, in its annual report to shareholders, in press
releases and other written materials and in oral statements made by
its officers, directors or employees to third parties. Such
statements involve certain risks and uncertainties that could cause
actual results to differ materially from those expressed or implied
in the forward-looking statements. These forward-looking statements
include, but are not limited to, statements about: the Company’s
goals and strategies; its future business development, financial
condition and results of operations; its ability to retain and grow
its customer base and network of medical centers; the growth of,
and trends in, the markets for its services in China; the demand
for and market acceptance of its brand and services; competition in
its industry in China; relevant government policies and regulations
relating to the corporate structure, business and industry;
fluctuations in general economic and business conditions in China.
Further information regarding these and other risks is included in
iKang’s filing with the Securities and Exchange Commission. iKang
undertakes no duty to update any forward-looking statement as a
result of new information, future events or otherwise, except as
required under applicable law.
IR Contact:
iKang Healthcare Group, Inc.Christy XieDirector
of Investor RelationsTel: +86 10 5320
8599Email: ir@ikang.comWebsite: www.ikanggroup.com
FleishmanHillardEmail:
ikang@fleishman.com
IKANG HEALTHCARE GROUP, INC. |
CONDENSED CONSOLIDATED BALANCE
SHEETS |
(In thousands of US dollars, except share data
and per share data) |
(Unaudited) |
|
|
|
|
|
As ofMarch 31, |
|
As ofDecember 31, |
|
2017 |
|
2017 |
|
|
|
|
|
|
|
|
ASSETS |
|
|
|
Current assets: |
|
|
|
Cash and
cash equivalents |
$ |
64,898 |
|
$ |
77,671 |
Restricted cash |
|
392 |
|
|
- |
Term
deposits |
|
4,359 |
|
|
- |
Accounts
receivable, net of allowance for doubtful accounts of $14,261 and
$20,530 as of March 31, 2017 and December 31, 2017,
respectively |
|
79,576 |
|
|
157,361 |
Inventories |
|
6,781 |
|
|
9,269 |
Deferred
tax assets-current |
|
9,635 |
|
|
12,724 |
Amount
due from related parties |
|
4,538 |
|
|
4,698 |
Prepaid
expenses and other current assets |
|
49,736 |
|
|
67,903 |
Total current
assets |
$ |
219,915 |
|
$ |
329,626 |
|
|
|
|
|
|
Property and equipment,
net |
$ |
163,081 |
|
$ |
170,146 |
Acquired intangible
assets, net |
|
25,852 |
|
|
22,863 |
Goodwill |
|
107,237 |
|
|
114,200 |
Long-term
investments |
|
180,758 |
|
|
188,814 |
Deferred tax
assets-non-current |
|
16,698 |
|
|
21,335 |
Rental deposit and
other non-current assets |
|
14,950 |
|
|
19,190 |
TOTAL ASSETS |
$ |
728,491 |
|
$ |
866,174 |
|
|
|
|
LIABILITIES, MEZZANINE
AND EQUITY |
|
|
|
Current
liabilities: |
|
|
|
Accounts
payable (including accounts payable of the consolidated VIEs
without recourse to iKang Healthcare Group, Inc. of $34,637 and
$47,226 as of March 31, 2017 and December 31, 2017,
respectively) |
$ |
39,892 |
|
$ |
55,989 |
Accrued
expenses and other current liabilities (including accrued expenses
and other current liabilities of the consolidated VIEs without
recourse to iKang Healthcare Group, Inc. of $48,910 and $73,595 as
of March 31, 2017 and December 31, 2017, respectively) |
|
59,278 |
|
|
89,020 |
Income
tax payable (including income tax payable of the consolidated VIEs
without recourse to iKang Healthcare Group, Inc. of $6,414 and
$21,785 as of March 31, 2017 and December 31, 2017,
respectively) |
|
11,951 |
|
|
29,906 |
Deferred
revenues (including deferred revenues of the consolidated VIEs
without recourse to iKang Healthcare Group, Inc. of $57,361 and
$80,804 as of March 31, 2017 and December 31, 2017,
respectively) |
|
64,740 |
|
|
87,690 |
Short
term borrowings (including short term borrowings of the
consolidated VIEs without recourse to iKang Healthcare Group, Inc.
of $111,299 and $168,399 as of March 31, 2017 and December 31,
2017, respectively) |
|
111,299 |
|
|
168,399 |
Total current
liabilities |
$ |
287,160 |
|
$ |
431,004 |
|
|
|
|
Long-term borrowings (including long term borrowings of the
consolidated VIEs and VIEs’ subsidiaries without recourse to iKang
Healthcare Group, Inc. of $101,697 and $10,836 as of March 31, 2017
and December 31, 2017, respectively) |
|
101,697 |
|
|
10,836 |
Deferred
tax liabilities-non-current (including deferred tax
liabilities non-current of the consolidated VIEs without
recourse to iKang Healthcare Group, Inc. of $7,009 and $5,171
as of March 31, 2017 and December 31, 2017, respectively) |
|
7,229 |
|
|
6,163 |
Long term payables |
|
- |
|
|
9,222 |
|
|
|
|
TOTAL LIABILITIES |
$ |
396,086 |
|
$ |
457,225 |
|
|
|
|
Equity: |
|
|
|
Total
iKang Healthcare Group, Inc. shareholders' equity |
|
312,437 |
|
|
383,916 |
Non-controlling interests |
|
19,968 |
|
|
25,033 |
|
|
|
|
TOTAL EQUITY |
$ |
332,405 |
|
$ |
408,949 |
|
|
|
|
TOTAL LIABILITIES AND
EQUITY |
$ |
728,491 |
|
$ |
866,174 |
|
|
|
|
IKANG HEALTHCARE GROUP, INC. |
|
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
|
(In thousands of US dollars, except share data
and per share data) |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Three-month periods |
|
Nine-month periods |
|
|
ended December 31 |
|
ended December 31 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
|
|
|
|
|
|
|
|
Net revenues |
$ |
154,569 |
|
|
$ |
206,390 |
|
|
$ |
375,556 |
|
|
$ |
474,406 |
|
|
Cost of revenues |
|
81,426 |
|
|
|
101,448 |
|
|
|
203,559 |
|
|
|
250,427 |
|
|
Gross profit |
$ |
73,143 |
|
|
$ |
104,942 |
|
|
$ |
171,997 |
|
|
$ |
223,979 |
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
|
Selling
and marketing expenses |
$ |
21,518 |
|
|
$ |
32,586 |
|
|
$ |
56,443 |
|
|
$ |
71,508 |
|
|
General
and administrative expenses |
|
23,864 |
|
|
|
23,783 |
|
|
|
65,009 |
|
|
|
61,085 |
|
|
Research
and development expenses |
|
851 |
|
|
|
835 |
|
|
|
2,485 |
|
|
|
2,301 |
|
|
Total operating
expenses |
$ |
46,233 |
|
|
$ |
57,204 |
|
|
$ |
123,937 |
|
|
$ |
134,894 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from
operations |
$ |
26,910 |
|
|
$ |
47,738 |
|
|
$ |
48,060 |
|
|
$ |
89,085 |
|
|
Interest expense |
|
4,370 |
|
|
|
10,036 |
|
|
|
10,733 |
|
|
|
16,291 |
|
|
Interest income |
|
188 |
|
|
|
64 |
|
|
|
801 |
|
|
|
305 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income
tax expenses and loss from equity method investments |
$ |
22,728 |
|
|
$ |
37,766 |
|
|
$ |
38,128 |
|
|
$ |
73,099 |
|
|
Income tax
expenses |
|
5,682 |
|
|
|
9,478 |
|
|
|
9,532 |
|
|
|
18,400 |
|
|
Loss from equity method
investments |
|
(2,920 |
) |
|
|
(350 |
) |
|
|
(6,082 |
) |
|
|
(2,775 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
$ |
14,126 |
|
|
$ |
27,938 |
|
|
$ |
22,514 |
|
|
$ |
51,924 |
|
|
Less: Net income
attributable to non-controlling interest |
|
90 |
|
|
|
848 |
|
|
|
491 |
|
|
|
1,780 |
|
|
Net income attributable
to iKang Healthcare Group, Inc. |
$ |
14,036 |
|
|
$ |
27,090 |
|
|
$ |
22,023 |
|
|
$ |
50,144 |
|
|
|
|
|
|
|
|
|
|
|
Net income attributable
to common shareholders of iKang Healthcare Group, Inc. |
$ |
14,036 |
|
|
$ |
27,090 |
|
|
$ |
22,023 |
|
|
$ |
50,144 |
|
|
|
|
|
|
|
|
|
|
|
Net income per share
attributable to common shareholders of iKang Healthcare Group,
Inc. |
|
|
|
|
|
|
|
|
Basic |
$ |
0.41 |
|
|
$ |
0.79 |
|
|
$ |
0.65 |
|
|
$ |
1.46 |
|
|
Diluted |
$ |
0.41 |
|
|
$ |
0.78 |
|
|
$ |
0.64 |
|
|
$ |
1.45 |
|
|
|
|
|
|
|
|
|
|
|
Net income per ADS (one
common share equals to two ADSs) |
|
|
|
|
|
|
|
|
Basic |
$ |
0.21 |
|
|
$ |
0.39 |
|
|
$ |
0.32 |
|
|
$ |
0.73 |
|
|
Diluted |
$ |
0.20 |
|
|
$ |
0.39 |
|
|
$ |
0.32 |
|
|
$ |
0.72 |
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares
used in calculating net income per common share |
|
|
|
|
|
|
|
|
Basic |
|
34,091,668 |
|
|
|
34,314,565 |
|
|
|
34,010,851 |
|
|
|
34,266,628 |
|
|
Diluted |
|
34,563,876 |
|
|
|
34,672,162 |
|
|
|
34,484,412 |
|
|
|
34,610,248 |
|
|
|
|
|
|
|
|
|
|
|
IKANG HEALTHCARE GROUP, INC. |
|
RECONCILIATION OF GAAP AND NON-GAAP
RESULTS |
|
(In thousands of US dollars, except share data
and per share data) |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Three-month periods |
|
Nine-month periods |
|
|
ended December 31 |
|
ended December 31 |
|
|
2016 |
|
2017 |
|
2016 |
|
2017 |
|
|
|
|
|
|
|
|
|
|
Income from
operations |
$ |
26,910 |
|
$ |
47,738 |
|
$ |
48,060 |
|
$ |
89,085 |
|
Add: |
|
|
|
|
|
|
|
|
Share-based compensation expenses |
|
489 |
|
|
389 |
|
|
1,462 |
|
|
1,162 |
|
Non-GAAP operating
income |
$ |
27,399 |
|
$ |
48,127 |
|
$ |
49,522 |
|
$ |
90,247 |
|
|
|
|
|
|
|
|
|
|
Net income attributable
to iKang Healthcare Group, Inc. |
$ |
14,036 |
|
$ |
27,090 |
|
$ |
22,023 |
|
$ |
50,144 |
|
Add: |
|
|
|
|
|
|
|
|
Share-based compensation expenses |
|
489 |
|
|
389 |
|
|
1,462 |
|
|
1,162 |
|
Non-GAAP net
income |
$ |
14,525 |
|
$ |
27,479 |
|
$ |
23,485 |
|
$ |
51,306 |
|
|
|
|
|
|
|
|
|
|
Income from
operations |
$ |
26,910 |
|
$ |
47,738 |
|
$ |
48,060 |
|
$ |
89,085 |
|
Add: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
9,395 |
|
|
10,582 |
|
|
27,442 |
|
|
31,162 |
|
Share-based compensation expenses |
|
489 |
|
|
389 |
|
|
1,462 |
|
|
1,162 |
|
Non-GAAP EBITDA |
$ |
36,794 |
|
$ |
58,709 |
|
$ |
76,964 |
|
$ |
121,409 |
|
|
|
|
|
|
|
|
|
|
Non-GAAP net income
attributable to common shareholders of iKang Healthcare Group,
Inc. |
$ |
14,525 |
|
$ |
27,479 |
|
$ |
23,485 |
|
$ |
51,306 |
|
|
|
|
|
|
|
|
|
|
Non-GAAP
net income per share attributable to common shareholders of iKang
Healthcare Group, Inc. |
|
|
|
|
|
|
|
Basic |
$ |
0.43 |
|
$ |
0.80 |
|
$ |
0.69 |
|
$ |
1.50 |
|
Diluted |
$ |
0.42 |
|
$ |
0.79 |
|
$ |
0.68 |
|
$ |
1.48 |
|
|
|
|
|
|
|
|
|
|
Non-GAAP net income per
ADS (one common share equals to two ADSs) |
|
|
|
|
|
|
|
|
Basic |
$ |
0.21 |
|
$ |
0.40 |
|
$ |
0.35 |
|
$ |
0.75 |
|
Diluted |
$ |
0.21 |
|
$ |
0.40 |
|
$ |
0.34 |
|
$ |
0.74 |
|
|
|
|
|
|
|
|
|
|
IKANG HEALTHCARE GROUP, INC. (NASDAQ:KANG)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
IKANG HEALTHCARE GROUP, INC. (NASDAQ:KANG)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024